Q3 2024 EPS Estimates for DURECT Co. Analyst Lows (NASDAQ:DRRX)

DURECT Co. (NASDAQ:DRRX – Free Report ) – Analysts at HC Wainwright lowered their Q3 2024 earnings estimates for shares of DURECT in a report issued on Wednesday, August 14th. HC Wainwright analyst E. Arce now expects that the specialty pharmaceutical company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.24). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for DURECT’s current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for DURECT’s Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.32) EPS and 2026 earnings at ($1.17) EPS.

DURECT (NASDAQ:DRRX – Get Your Free Report ) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. DURECT had a negative net margin of 279.77% and a negative return on equity of 328.25%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $2.49 million. In the same quarter last year, the business posted EPS of ($0.46).

Separately, StockNews.com cut shares of DURECT from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. DURECT currently has an average rating of “Hold” and a consensus price target of $21.00, according to MarketBeat.

Read our latest review on DURECT

DURECT trading down 2.6%

Shares of DURECT stock opened at $1.12 on Friday. The stock has a market cap of $34.76 million, a price-to-earnings ratio of -1.18 and a beta of 1.03. The company has a fifty day simple moving average of $1.46 and a 200 day simple moving average of $1.19. DURECT has a 12 month low of $0.47 and a 12 month high of $3.36.

Institutional trading of DURECT

A number of large investors have recently bought and sold shares of DRRX. Richmond Brothers Inc. purchased a new position in DURECT in the 4th quarter worth $306,000. Accredited Investors Inc. purchased a new position in DURECT in the second quarter worth $113,000. Tocqueville Asset Management LP grew its position in DURECT by 10.8% in the first quarter. Tocqueville Asset Management LP now owns 256,220 shares of the specialty pharmaceutical company’s stock worth $310,000 after purchasing an additional 25,000 shares in the last quarter. Gagnon Securities LLC raised its position in DURECT by 6.0% in the first quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock worth $460,000 after buying an additional 21,425 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after bought an additional 6,300 shares in the last quarter. Institutional investors and hedge funds own 28.03% of the company’s shares.

About DURECT

(Get a free report)

DURECT Corporation, a biopharmaceutical company, is developing drugs based on its epigenetic regulation program. The company’s lead product, larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule, is in Phase IIb to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival for the treatment of hepatitis associated with alcohol. , as well as a completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Recommended articles

Get news and reviews for DURECT daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DURECT and related companies with MarketBeat.com’s FREE daily email newsletter.